36 — SSMO — Session

Oral presentation Clinical solid tumor oncology

Wednesday, 19 Nov 2025, 1:45 p.m. - 3:15 p.m., Kairo 1-2

Chair: Christian Britschgi (Cantonal Hospital Winterthur), Mascha Binder (Unispital Basel)

Perioperative chemo-immunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma: final analysis of the single arm phase II trial SAKK 06/17

Presentation time: 10 min Discussion time: 4 min

Speaker: Cathomas (Cantonal Hospital Graubünden)

Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer: interim analysis of SAKK 06/19 study

Presentation time: 10 min Discussion time: 4 min

Speaker: Cathomas (Cantonal Hospital Graubünden)

Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001–2020): A Meta-Analysis of Pivotal Randomized Controlled Trials

Presentation time: 10 min Discussion time: 4 min

Speaker: Rahimzadeh (University of Zurich)

Co-Alterations Associated with Resistance to EGFR-Inhibitors in EGFR+ NSCLC: Insights from the Precision Oncology Program in Two International Real-World Cohorts

Presentation time: 10 min Discussion time: 4 min

Speaker: Boos (University Hospital Zurich)

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

Presentation time: 10 min Discussion time: 4 min

Speaker: Schultheiss (University Hospital Basel)

Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy (SAKK 16/14)

Presentation time: 10 min Discussion time: 4 min

Speaker: Da Silva (University of Basel)